Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
COLUMN
Maurer’s Healthcare Insight (142)
Another Look at Boiled Frogs P. Reed Maurer Long-time loyal readers will recall an article I wrote 10 years ago, to be exact April 15, 2002, entitled “Too Many Boiled Frogs.” My characterization of certain companies (unnamed) as boiled frogs…
To read the full story
COLUMN
- Japan’s Healthcare Pulse: An 18-Month Market Snapshot
October 30, 2026
- New York Note - 1: JETRO’s Role in Connecting Japan with the World
October 23, 2026
- Outside the Bubble: Lunch with Pharma Delegates
September 30, 2026
- The One Mistake on Your Resume
August 31, 2026
- Why Your Brain Wants You to Stay (Even When You Want to Go)
July 31, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…